<What are the parallels between INCY at MDGL at this stage?>
There are none. INCY was/is R&D engine, MDGL is not. When business was not going well at INCY (2002-2008, CCR programs) Friedman was effective in refocus (2008/9) toward JAK keeping Jakafi US market, and licenses ex-US to Novartis, and deal with Lilly. Was he part of the 2002-8 WASTE? Yes!
Now, at MDGL he has +2M Shares (+10%) interest, and only way to produce return is 3196. Buying 10K shares in open market may signal his confidence, but to me is more like "market manipulation", than anything else. I doubt very much that he is interested to cross finishing line on its own! He need strong partner or acquisition? He tried to play strong "poker hand" with not more than good "pair", and now is paying price, IMO. |
